Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELRISE MF: elritercept versus placebo in myelofibrosis-associated anemia on ruxolitinib
jRCT2031260378Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Sep 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in myelofibrosis (MF) comparing Elritercept + ruxolitinib with Placebo + ruxolitinib (2 arms). Primary endpoint: Proportion of participants who are red blood cell transfusion independent for any consecutive 12-week period. Started Sep 2026; status: recruiting.
02
Drugs
elritercept
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on jRCT2031260378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260378.